Treatment with dolutegravir and either of 2 tenofovir prodrugs, tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, is noninferior to standard HIV antiretroviral regimes.
Although adding ibalizumab to an optimized background regimen of ART is not cost-effective, ibalizumab substantially increased survival for individuals with multidrug-resistant HIV.
Monthly injections of long-acting formulations of cabotegravir and rilpivirine were noninferior to daily oral combination antiretroviral therapy for maintaining HIV-1 suppression and also offered improved treatment satisfaction.
Fostemsavir-containing regimens remained generally well tolerated through 96 weeks of treatment according to data from the BRIGHTE phase 3 trial.
Dolutegravir-based regimens in patients with acute HIV-1 infections who started ART early showed good viro-immunologic efficacy.
Avirulins may provide a valuable chemical foundation for the development of the next generation of prophylactic medications for HIV-1 in women, according to results of a study presented at American Society of Microbiology (ASM) Microbe 2019 held from June 20-24, 2019, in San Francisco, California. Although much progress has been made in decreasing the risk…
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pomalyst (pomalidomide; Celgene) for the treatment of patients with Kaposi sarcoma.
Analytical treatment interruption caused neither expansion of HIV reservoirs nor immunologic abnormalities after reinitiation of antiretroviral therapy.
Suppression maintained for up to 16 weeks in HIV-infected undergoing analytic treatment interruption
Recombinant human-lactoferrin treatment in PLWHIV receiving ART was not associated with significant improvements in inflammation or immune activation.
